Clinical trials
Cancer Risk clinical trials
Below are recruiting cancer risk clinical trials, each written for real people, not researchers. We’re tracking 721 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06335420Recruiting
Can carrot juice prevent colon polyps from coming back?
This study tests whether drinking carrot juice every day can lower the chance that large colon polyps or early colon cancers will come back. Researchers want to see if the nutrients in carrot juice help protect the lining of the colon.
OdenseAges 18 years+ - NCT06268405Recruiting
PET scan and blood test for high-risk breast screening
This study tests a new PET scan machine for the breast (positron emission mammography) along with a blood test called a liquid biopsy for women who need a biopsy after a high-risk breast screening. It may help find cancer more accurately and less invasively.
Toronto, OntarioAges 18 years+ - NCT04912739Recruiting
Targeted health conversations in primary care
This study offers targeted health dialogues with people receiving care in primary settings, to see how well these conversations can support health. You may be invited because of your age and where you receive healthcare in Skåne County.
Malmö, Skåne CountyAges 40–70 - NCT07076485RecruitingPhase 2
Shorter radiation after surgery for node-positive breast cancer
This trial tests shorter radiation schedules for people with breast cancer that has spread to lymph nodes or is high-risk. It aims to find a shorter course of radiation that is just as effective after surgery.
Loveland, ColoradoAges 18 years+ - NCT05834764RecruitingPhase 2
Pyrotinib for high-risk HER2-positive early breast cancer
This Phase 2 trial tests pyrotinib, a HER2-targeted cancer medicine, in people with high-risk, HER2-positive breast cancer after surgery. It aims to lower the chance the cancer comes back, especially when standard treatment did not fully clear the tumor.
Nanjing, JiangsuAges 18–75 - NCT06261190Enrolling by invitation
Active monitoring for low-risk thyroid cancer
This trial tests whether it is safe to avoid immediate surgery and instead monitor small thyroid cancers that are considered low-risk. If you join, doctors will check regularly to make sure the cancer does not grow or spread.
Goyang-siAges 18 years+ - NCT05295407Recruiting
Testing a risk assessment to predict prostate cancer on biopsy
This trial studies whether a risk assessment can better predict who actually has prostate cancer based on information collected around the biopsy. It may help doctors decide what biopsy findings mean for people with certain PSA (a blood test) results.
Evanston, IllinoisAges 40–69 - NCT07436741RecruitingPhase 3
Study of surufatinib plus chemo before surgery for pancreatic cancer
This trial tests if adding surufatinib to standard chemotherapy before surgery can help people with a certain type of pancreatic cancer. The goal is to see if the combination shrinks the tumor more than chemotherapy alone.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06520683RecruitingPhase 3
Immunotherapy after surgery for high-risk stage II colorectal cancer
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
Guangzhou, GuangdongAges 18–80 - NCT07475403RecruitingPhase 2
Immunotherapy guided by urine DNA for high risk bladder cancer
This trial tests a new immunotherapy approach for people with a very high risk type of bladder cancer that hasn't spread into the muscle layer. The treatment is guided by a special urine test that looks for tumor DNA, and it may help if surgery cannot remove all the cancer or you choose not to have your bladder removed.
TianjinAges 18 years+ - NCT07408531Recruiting
AI-enhanced lung cancer screening study
This trial uses artificial intelligence to better predict your lung cancer risk from your low-dose CT scan. You will watch a short video, answer a survey, and optionally give a blood sample to help improve future screening.
Chicago, IllinoisAges 50–80 - NCT07130578Recruiting
Urine DNA test to guide second bladder cancer surgery
This trial is testing whether a urine test for tumor DNA/RNA can help guide the decision for a second surgery in people with high-risk, non-muscle-invasive bladder cancer. It aims to see if the urine test can predict who needs the second surgery, potentially avoiding unnecessary procedures.
TianjinAges 18 years+ - NCT07046585Recruiting
Blood test for colon cancer screening
This trial tests a new blood test to screen for colorectal cancer in people at average risk. You would give a blood sample before your scheduled colonoscopy, and the results will be compared to the colonoscopy findings.
Austin, TexasAges 40 years+ - NCT07503847Enrolling by invitation
Colorectal Cancer Screening for Ages 40-49 with Family History
This trial helps people aged 40-49 who have a parent, sibling, or child with colorectal cancer decide on the best way to get screened. It aims to find the most effective screening method for those at higher risk.
TaipeiAges 40–49 - NCT06427824Recruiting
Health tests for older adults with bladder cancer before bladder removal
This study looks at how a series of health tests (called a comprehensive geriatric assessment) can help doctors plan care for older adults with bladder cancer who are having their bladder removed. The goal is to improve recovery and quality of life.
Chicago, IllinoisAges 65 years+ - NCT06283576Enrolling by invitation
Pancreatic cancer early detection with blood test
This trial studies a blood test to find pancreatic cancer early. It may help people who are at risk or have suspicious signs.
StockholmAges 18 years+ - NCT05044689Recruiting
Study to find risk factors for breast and colon cancer
This study is trying to understand what factors might raise the risk of breast cancer and colon (large bowel) cancer. You may be enrolled either if you have a confirmed cancer diagnosis (cases) or if you do not have cancer (controls).
Ile-Ife, Osun StateAges Any age - NCT06950697Recruiting
Blood clot risk prediction for lung cancer patients on immunotherapy
This study builds a tool to predict blood clot risk in lung cancer patients receiving immune checkpoint inhibitors. Researchers will use your data to develop a more personalized risk assessment, which may help prevent dangerous clots during treatment.
Zhengzhou, HenanAges 18 years+ - NCT04444869RecruitingPhase 2
Lower-dose radiation with chemotherapy for low-risk HPV throat cancer
This trial tests whether a less intense (lower-dose) radiation plan, combined with chemotherapy, can control HPV-positive oropharyngeal (throat) cancer with fewer side effects. It targets people considered “low-risk” based on tumor size and lymph node involvement.
Columbia, MissouriAges 18 years+ - NCT05086614RecruitingPhase 3
Thymosin-alpha 1 after surgery for high-risk colon cancer
This trial looks at whether thymosin-alpha 1, an immune-support treatment, can help prevent colon cancer from coming back after surgery. It targets people with high-risk stage II or III colon cancer who have had the tumor removed.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06382818Recruiting
Personalized breast radiation based on risk and side effects
This trial tests whether radiation therapy can be personalized based on your risk of the cancer coming back and your risk of side effects from radiation. Depending on those factors, you may receive a tailored radiation plan that could be more or less intense.
MontpellierAges 18 years+ - NCT07120282RecruitingPhase 2
Tislelizumab after surgery for early-stage lung cancer
This trial tests whether a drug called tislelizumab, given after surgery, can help prevent lung cancer from coming back. It is for people with stage I non-small cell lung cancer who have certain high-risk features and a protein called PD-L1 on their tumor cells.
BeijingAges 18 years+ - NCT06449313RecruitingPhase 2
Immunotherapy before lung cancer surgery for stage 3 disease
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help shrink stage 3 lung cancer and improve outcomes. The goal is to make the tumor easier to remove and possibly lower the chance of it coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT03561740RecruitingPhase 3
Capecitabine plus usual treatment for high-risk HER2 breast cancer
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
Guangzhou, GuangdongAges 18–70
Hear when a new Cancer Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer risk?
- Yes. Clin2 currently lists 721 recruiting cancer risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.